Len Neckers Selected Research

(2,4- dihydroxy- 5- isopropylphenyl)- (5- (4- methylpiperazin- 1- ylmethyl)- 1,3- dihydroisoindol- 2- yl)methanone

12/2020	Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
1/2017	Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics.
8/2015	Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Len Neckers Research Topics

Disease

83	Neoplasms (Cancer) 06/2022 - 01/2002
12	Hypoxia (Hypoxemia) 01/2022 - 01/2002
10	Carcinogenesis 06/2022 - 11/2003
10	Neoplasm Metastasis (Metastasis) 01/2016 - 11/2003
9	Kidney Neoplasms (Kidney Cancer) 12/2014 - 09/2004
8	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 05/2002
7	Renal Cell Carcinoma (Grawitz Tumor) 12/2019 - 09/2004
7	Breast Neoplasms (Breast Cancer) 07/2018 - 01/2002
5	Leiomyomatosis 12/2019 - 01/2007
4	Urinary Bladder Neoplasms (Bladder Cancer) 01/2017 - 01/2011
4	Lung Neoplasms (Lung Cancer) 01/2017 - 04/2002
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018 - 04/2007
3	Disease Progression 01/2010 - 01/2007
3	Mast-Cell Leukemia (Leukemia, Mast Cell) 05/2008 - 02/2004
3	Inflammation (Inflammations) 10/2007 - 03/2003
3	Necrosis 10/2007 - 03/2003
2	Alzheimer Disease (Alzheimer's Disease) 01/2018 - 04/2007
2	Carcinoma (Carcinomatosis) 01/2017 - 10/2008
2	Hereditary leiomyomatosis and renal cell cancer 08/2009 - 02/2007
2	Mast Cell Activation Disorders (Mast-Cell Disease) 05/2008 - 04/2004
2	Colitis 04/2006 - 09/2005
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2005 - 02/2004
2	Mastocytosis 04/2004 - 02/2004
1	Nausea 12/2020
1	Diarrhea 12/2020
1	Mucositis 12/2020
1	Vomiting 12/2020
1	Fatigue 12/2020
1	Neurofibromatosis 1 (Neurofibromatosis Type I) 01/2019
1	Chronic Disease (Chronic Diseases) 01/2018
1	Bacterial Infections (Bacterial Infection) 01/2018
1	Sarcoma (Soft Tissue Sarcoma) 10/2016
1	Osteosarcoma (Osteogenic Sarcoma) 10/2016

Drug/Important Bio-Agent (IBA)

39	Proteins (Proteins, Gene)FDA Link 12/2020 - 01/2002
34	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2019 - 01/2002
28	Molecular Chaperones (Chaperone, Molecular)IBA 02/2016 - 01/2002
16	Pharmaceutical PreparationsIBA 12/2020 - 05/2002
12	Phosphotransferases (Kinase)IBA 09/2015 - 05/2002
8	Oncogene Proteins (Oncogene Protein)IBA 01/2016 - 04/2002
8	tanespimycin (17AAG)IBA 01/2013 - 02/2003
8	geldanamycinIBA 01/2013 - 05/2002
7	Fumarate Hydratase (Fumarase)IBA 12/2019 - 08/2005
6	EnzymesIBA 12/2019 - 02/2007
5	Tyrosine Kinase InhibitorsIBA 06/2022 - 05/2002
5	Oxygen (Dioxygen)IBA 01/2022 - 04/2004
4	Tyrosine (L-Tyrosine)FDA Link 08/2015 - 05/2002
4	Transcription Factors (Transcription Factor)IBA 01/2012 - 01/2002
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2007 - 01/2002
3	(2,4- dihydroxy- 5- isopropylphenyl)- (5- (4- methylpiperazin- 1- ylmethyl)- 1,3- dihydroisoindol- 2- yl)methanoneIBA 12/2020 - 08/2015
3	STA 9090IBA 01/2017 - 01/2013
3	Histones (Histone)IBA 01/2017 - 04/2002
3	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2015 - 08/2009
3	Glucose (Dextrose)FDA LinkGeneric 08/2014 - 08/2009
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2012 - 09/2008
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 06/2022 - 01/2019
2	SNX 2112IBA 06/2022 - 01/2017
2	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 01/2022 - 07/2018
2	Biomarkers (Surrogate Marker)IBA 12/2020 - 01/2017
2	NucleotidesIBA 07/2018 - 05/2002
2	Dasatinib (BMS 354825)FDA Link 02/2018 - 10/2008
2	ProteomeIBA 01/2017 - 09/2011
2	Protein Kinases (Protein Kinase)IBA 09/2015 - 09/2008
2	FumaratesIBA 12/2014 - 08/2005
2	Insulin (Novolin)FDA Link 02/2013 - 07/2006
2	Hormones (Hormone)IBA 01/2013 - 05/2002
2	beta CateninIBA 01/2013 - 05/2008
2	Cisplatin (Platino)FDA LinkGeneric 08/2012 - 10/2010
2	Androgen Receptors (Androgen Receptor)IBA 03/2012 - 11/2003
2	Biological ProductsIBA 05/2011 - 01/2006
2	Bortezomib (Velcade)FDA Link 10/2010 - 05/2004
2	UbiquitinIBA 01/2010 - 09/2004
2	Gefitinib (Iressa)FDA Link 09/2008 - 11/2003
2	Histone Deacetylase InhibitorsIBA 03/2006 - 04/2002
2	Imatinib Mesylate (Gleevec)FDA Link 10/2005 - 04/2004
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2005 - 03/2003
2	Anti-Bacterial Agents (Antibiotics)IBA 02/2005 - 02/2004
2	ErbB Receptors (EGF Receptor)IBA 09/2004 - 05/2002
2	Rifabutin (Ansamycin)FDA Link 02/2004 - 02/2003
1	4- (2,6- dichlorobenzoylamino)- 1H- pyrazole- 3- carboxylic acid piperidin-4-ylamideIBA 12/2020
1	Proteasome Endopeptidase Complex (Proteasome)IBA 12/2019
1	Positive Transcriptional Elongation Factor BIBA 01/2019
1	TOR Serine-Threonine KinasesIBA 01/2019
1	AMP-Activated Protein KinasesIBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 01/2019
1	benzothiazoleIBA 07/2018
1	5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA 01/2017
1	CUDC 305IBA 01/2017
1	STA-12-8666IBA 10/2016
1	Irinotecan (Camptosar)FDA LinkGeneric 10/2016
1	Topoisomerase I InhibitorsIBA 10/2016
1	Indicators and Reagents (Reagents)IBA 02/2016
1	Adenosine Triphosphatases (ATPase)IBA 01/2016
1	Endoplasmic Reticulum Chaperone BiPIBA 01/2016
1	Complement System Proteins (Complement)IBA 09/2015
1	LipidsIBA 03/2015

Therapy/Procedure

17	Therapeutics 01/2019 - 05/2002
2	Drug Therapy (Chemotherapy) 03/2015 - 08/2012
2	Cystectomy 12/2011 - 01/2011
2	Urinary Diversion (Ileal Conduit) 12/2011 - 01/2011
1	Castration 01/2022